11:10 AM
Oct 12, 2018
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Phase II data for Merck's Btk inhibitor highlighted at ECTRIMS

Merck KGaA (Xetra:MRK) reported 24-week data from a Phase II trial to treat relapsing multiple sclerosis showing that evobrutinib (M2951) reduced the mean total number of gadolinium-enhancing T1 lesions by up to 2.7 over placebo. The compound is an oral Bruton's tyrosine kinase (Btk) inhibitor that Merck discovered in-house. Data were presented at the European Committee for Treatment and Research in Multiple Sclerosis meeting in Berlin.

Merck reported in March that evobrutinib met the primary endpoints in the trial of reducing the total number of gadolinium-enhancing T1 lesions from baseline to weeks 12,...

Read the full 443 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >